Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T12355 | Target Info | |||
| Target Name | G1/S-specific cyclin-D1 (CCND1) | ||||
| Synonyms |
PRAD1 oncogene; PRAD1; Cyclin D1; BCL1; BCL-1 oncogene; BCL-1; B-cell lymphoma 1 protein
Click to Show/Hide
|
||||
| Target Type | Clinical trial Target | ||||
| Gene Name | CCND1 | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Apoptosis regulator Bcl-2 (BCL-2) | Successful Target | ||||
| UniProt ID | BCL2_HUMAN | |||||
| Gene Name | BCL2 | |||||
| Synonyms |
Bcl-2
Click to Show/Hide
|
|||||
| Representative Drug(s) | ABT-263 | Drug Info | Ki < 0.01 nM | [1] | ||
| Co-Target Name | Apoptosis regulator Bcl-xL (BCL-xL) | Clinical trial Target | ||||
| UniProt ID | B2CL1_HUMAN | |||||
| Gene Name | BCL2L1 | |||||
| Synonyms |
Bcl2like protein 1; Bcl2L1; Bcl2-L-1; Bcl-XL; Bcl-2-like protein 1; BCLX; BCL2L; Apoptosis regulator Bcl-X
Click to Show/Hide
|
|||||
| Representative Drug(s) | ABT-263 | Drug Info | Ki = 0.055 nM | [2] | ||
| Co-Target Name | Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) | Clinical trial Target | ||||
| UniProt ID | MCL1_HUMAN | |||||
| Gene Name | MCL1 | |||||
| Synonyms |
mcl1/EAT; Bcl2-L-3; Bcl-2-related protein EAT/mcl1; Bcl-2-like protein 3; BCL2L3
Click to Show/Hide
|
|||||
| Representative Drug(s) | ABT-263 | Drug Info | Ki < 1 nM | [3] | ||
| Co-Target Name | Apoptosis regulator Bcl-W (BCL-W) | Clinical trial Target | ||||
| UniProt ID | B2CL2_HUMAN | |||||
| Gene Name | BCL2L2 | |||||
| Synonyms |
KIAA0271; Bcl2-L-2; Bcl-2-like protein 2; BCLW
Click to Show/Hide
|
|||||
| Representative Drug(s) | ABT-263 | Drug Info | IC50 = 70 nM | [4] | ||
| Co-Target Name | Bcl2-antagonist of cell death (BAD) | Co-Target | ||||
| UniProt ID | BAD_HUMAN | |||||
| Gene Name | BAD | |||||
| Synonyms |
Bcl2-associated agonist of cell death; BAD; Bcl-2-binding component 6; Bcl-2-like protein 8; Bcl2-L-8; Bcl-xL/Bcl-2-associated death promoter; Bcl2 antagonist of cell death
Click to Show/Hide
|
|||||
| Representative Drug(s) | ABT-263 | Drug Info | Ki < 0.5 nM | [5] | ||
| Co-Target Name | Bcl-2-like protein 1-Bcl-2-like protein 11 complex | Co-Target | ||||
| UniProt ID | B2CL1_HUMAN-B2L11_HUMAN | |||||
| Gene Name | BCL2L1-BCL2L11 | |||||
| Representative Drug(s) | ABT-263 | Drug Info | IC50 = 4.3 nM | [6] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Clinical candidates modulating protein-protein interactions: The fragment-based experience. Eur J Med Chem. 2019 Apr 1;167:76-95. | ||||
| REF 2 | Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. J Med Chem. 2018 Apr 12;61(7):2636-51. | ||||
| REF 3 | The chemical biology of apoptosis: Revisited after 17 years. Eur J Med Chem. 2019 Sep 1;177:63-75. | ||||
| REF 4 | Discovery and optimization of covalent Bcl-xL antagonists. Bioorg Med Chem Lett. 2019 Dec 1;29(23):126682. | ||||
| REF 5 | Recent developments in fragment-based drug discovery. J Med Chem. 2008 Jul 10;51(13):3661-80. | ||||
| REF 6 | Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. Eur J Med Chem. 2015 Jan 27;90:315-331. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.